[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[3] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[4] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[5] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[6] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[7] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|
[8] |
CHEN Shuang, ZHENG Shufen, ZHANG Shuyao, ZHONG Shilong.
Adverse reactions of tumor immunotherapy drugs—PD-1/PD-L1 inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1107-1112.
|
[9] |
ZHENG Mingjie, ChENG Rong, SONG Haibo.
Bibliometric Analysis of Pharmacovigilance Research in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 686-688.
|
[10] |
Chen Aihong, Yin Qiangbing, Li Huadan, Wu Nengjian.
Analysis of Monitoring Reports on Suspected Adverse Events Following Immunization in Pingshan District Shenzhen City during 2015~2018
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 464-468.
|
[11] |
FAN Yan, WANG Dan, WANG Chunting.
The Mechanism of Toxicity Reaction Induced by Protamine Sulfate Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1159-1161.
|
[12] |
XUE Wei, QI Wenyuan, LIU Yue, CONG Duanduan, LIU Xiaohui, LI Hongyan, WANG Juan, LI Kexin, HU Xin.
Design and Implementation of Bioequivalence Tests Based on Risk Management Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 549-552.
|
[13] |
LI Xinxu, TANG Zhimin, ZHOU Jun, WANG Jun.
Limitations of the Safety Assessment in Premarketing Clinical Trials of Drugs and Suggestions for Improvement
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 465-470.
|
[14] |
YANG Yue.
Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 65-71.
|
[15] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Implementation of US FDA's Drug Risk Evaluation and Mitigation Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 871-876.
|